R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Rare Disease R&D: one step forward, but a long road ahead

With over 40% of all medicines in the pipeline aimed at rare diseases, the future looks positive for increasing the number of treatments available.

Patients

To help solve patient distrust in pharma, industry collabora...

The past two years have shone a spotlight on the UK life sciences industry.

R&D

Deep Dive: Research and Development

Fuelled by advancements in technology and computing, R&D in life sciences is undergoing a fundamental transformation that puts patients at the heart of research.

R&D

Coalition issues rallying cry to takes the fight against AMR...

Team up, wake up, and act before AMR turns back the clock on medical advances, say the cross-sector team behind the Infection Management Coalition.

R&D

Examining COVID’s impact on clinical research participant di...

The clinical research industry has long struggled with participant diversity.

R&D

New HIV variant highlights the importance of monitoring viru...

Researchers discovered a highly virulent variant of HIV in the Netherlands that genetic sequence analysis suggests has been circulating since the 1990s.